These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 16843173)

  • 21. [Coronary stents. Where are we? Where are we going?].
    Gaxiola E; Vlietstra RE; Pepine CJ
    Arch Inst Cardiol Mex; 1998; 68(4):337-45. PubMed ID: 9810372
    [No Abstract]   [Full Text] [Related]  

  • 22. The impact of general usage of stents on short- and long-term health care costs following percutaneous coronary intervention.
    Odell A; Landelius P; Astrom-Olsson K; Grip L
    Cardiology; 2008; 109(2):85-92. PubMed ID: 17664872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug-eluting balloons for percutaneous coronary interventions.
    Zimarino M; De Caterina R
    Thromb Haemost; 2009 Jan; 101(1):9-11. PubMed ID: 19132182
    [No Abstract]   [Full Text] [Related]  

  • 24. [Clinical and economic cost-benefit relations in treatment of patients with coronary heart disease].
    Höher M; Hombach V
    Z Kardiol; 1998; 87 Suppl 2():8-19. PubMed ID: 9827456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inflation time and drug-eluting stent: the longer, the better..
    Bertrand OF
    Catheter Cardiovasc Interv; 2009 Feb; 73(2):212-3. PubMed ID: 19156881
    [No Abstract]   [Full Text] [Related]  

  • 26. Drug-eluting stent update 2007: part III: Technique and unapproved/unsettled indications (left main, bifurcations, chronic total occlusions, small vessels and long lesions, saphenous vein grafts, acute myocardial infarctions, and multivessel disease).
    Colombo A; Chieffo A
    Circulation; 2007 Sep; 116(12):1424-32. PubMed ID: 17875983
    [No Abstract]   [Full Text] [Related]  

  • 27. "Neither horseshoes nor hand grenades"--does close count in percutaneous coronary revascularization?
    Bailey SR
    Catheter Cardiovasc Interv; 2008 Oct; 72(4):457-8. PubMed ID: 18819143
    [No Abstract]   [Full Text] [Related]  

  • 28. The need for a dedicated bifurcation stenting system.
    Kornowski R
    Catheter Cardiovasc Interv; 2009 Apr; 73(5):641-2. PubMed ID: 19309702
    [No Abstract]   [Full Text] [Related]  

  • 29. Patterns and outcomes of drug-eluting coronary stent use in clinical practice.
    Rao SV; Shaw RE; Brindis RG; Klein LW; Weintraub WS; Krone RJ; Peterson ED
    Am Heart J; 2006 Aug; 152(2):321-6. PubMed ID: 16875917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paclitaxel-eluting stents for the treatment of complex coronary lesions: immediate and 12-month results.
    Sheiban I; Ballari GP; Moretti C; Marra WG; Meliga E; Omedè P; Sciuto F; Trevi GP
    J Cardiovasc Med (Hagerstown); 2007 Aug; 8(8):582-8. PubMed ID: 17667028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dollars and stents: is reimbursement floating out of reach?
    Rohland P
    J Cardiovasc Manag; 1999; 10(6):16-7. PubMed ID: 10662365
    [No Abstract]   [Full Text] [Related]  

  • 32. Comparative healing response after sirolimus- and paclitaxel-eluting stent implantation in a pig model of restenosis.
    Silva GV; Fernandes MR; Madonna R; Clubb F; Oliveira E; Jimenez-Quevedo P; Branco R; Lopez J; Angeli FS; Sanz-Ruiz R; Vaughn WK; Zheng Y; Baimbridge F; Canales J; Cardoso CO; Assad JA; Falotico R; Perin EC
    Catheter Cardiovasc Interv; 2009 May; 73(6):801-8. PubMed ID: 19309735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel paclitaxel-eluting dedicated bifurcation stent: a case report from the first human use Taxus Petal trial.
    Johnson TW; Kay IP; Ormiston JA
    Catheter Cardiovasc Interv; 2009 Apr; 73(5):637-40. PubMed ID: 19213074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Understanding the drug-eluting stent trials.
    Coolong A; Kuntz RE
    Am J Cardiol; 2007 Sep; 100(5A):17K-24K. PubMed ID: 17719349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paclitaxel-eluting balloon: from bench to bed.
    De Labriolle A; Pakala R; Bonello L; Lemesle G; Scheinowitz M; Waksman R
    Catheter Cardiovasc Interv; 2009 Apr; 73(5):643-52. PubMed ID: 19309715
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The turmoil around the drug-eluting stents.
    Werkö L
    Scand Cardiovasc J; 2007 Jun; 41(3):131-2. PubMed ID: 17487758
    [No Abstract]   [Full Text] [Related]  

  • 37. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
    Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transradial arterial access: economic considerations.
    Caputo RP
    J Invasive Cardiol; 2009 Aug; 21(8 Suppl A):18A-20A. PubMed ID: 19734570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stenting unprotected left main: the outcome is not always favorable.
    Colombo A
    Catheter Cardiovasc Interv; 2008 Mar; 71(4):539-40. PubMed ID: 18307235
    [No Abstract]   [Full Text] [Related]  

  • 40. Percutaneous revascularization of the "unprotected" left main during acute myocardial infarction: "Dare to struggle! Dare to win!".
    Morrison DA
    Catheter Cardiovasc Interv; 2009 Jan; 73(1):22-4. PubMed ID: 19089931
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.